High Court On Corex

Delhi High Court stayed on Thursday a government ban on 344 drugs that it deemed lacked therapeutic efficacy, after over six months of hearing more than 300 petitions filed by drugmakers against it.

The Delhi High Court is likely to pronounce today its verdict on 454 petitions filed by drug and healthcare majors challenging the Centre's decision to ban 344 fixed dose combination (FDC) medicines, including well known brands like Corex cough syrup, Vicks Action 500 extra and D'Cold.

The Delhi High Court on Thursday reserved its verdict in over 450 petitions filed by drug and healthcare majors challenging the Centre's decision to ban 344 fixed dose combination (FDC) medicines, including well-known brands like Corex cough syrup, Vicks Action 500 extra and D'Cold.

Government on Monday sought vacation of Delhi High Court's interim order staying the ban on some fixed dose combinations (FDC) medicines, saying it would be "against public interest and patient safety" and alleging that the drug firms' sole objective was to make profits.

Pharma majors Abbott Healthcare and Macleods Pharmaceuticals on Tuesday got interim relief from the Delhi High Court which stayed till March 21 Government's decision banning sale of certain combination medicines of the two companies.

Delhi High Court granted U.S. drugmaker Pfizer an interim injunction on a ban on its popular cough syrup Corex, days after the government ordered it to be prohibited citing a potential risk to humans.

The Delhi High Court has said that for now, a government ban on popular cough syrup Corex, made by US pharma Pfizer, will not hold. The court will next hear the case on Monday.

The High Court will hear the case in a week. The ban on Pfizer's cough syrup was part of a wider notice issued by the government over the weekend prohibiting the sale and manufacture of 344 combination drugs blacklisted by a panel of experts.

The ban on Pfizer's cough syrup was part of a wider notice issued by the government over the weekend ordering prohibition of the sale and manufacture of 344 combination drugs that a panel of experts found posed a risk to humans.

Delhi High Court stayed on Thursday a government ban on 344 drugs that it deemed lacked therapeutic efficacy, after over six months of hearing more than 300 petitions filed by drugmakers against it.

The Delhi High Court is likely to pronounce today its verdict on 454 petitions filed by drug and healthcare majors challenging the Centre's decision to ban 344 fixed dose combination (FDC) medicines, including well known brands like Corex cough syrup, Vicks Action 500 extra and D'Cold.

The Delhi High Court on Thursday reserved its verdict in over 450 petitions filed by drug and healthcare majors challenging the Centre's decision to ban 344 fixed dose combination (FDC) medicines, including well-known brands like Corex cough syrup, Vicks Action 500 extra and D'Cold.

Government on Monday sought vacation of Delhi High Court's interim order staying the ban on some fixed dose combinations (FDC) medicines, saying it would be "against public interest and patient safety" and alleging that the drug firms' sole objective was to make profits.

Pharma majors Abbott Healthcare and Macleods Pharmaceuticals on Tuesday got interim relief from the Delhi High Court which stayed till March 21 Government's decision banning sale of certain combination medicines of the two companies.

Delhi High Court granted U.S. drugmaker Pfizer an interim injunction on a ban on its popular cough syrup Corex, days after the government ordered it to be prohibited citing a potential risk to humans.

The Delhi High Court has said that for now, a government ban on popular cough syrup Corex, made by US pharma Pfizer, will not hold. The court will next hear the case on Monday.

The High Court will hear the case in a week. The ban on Pfizer's cough syrup was part of a wider notice issued by the government over the weekend prohibiting the sale and manufacture of 344 combination drugs blacklisted by a panel of experts.

The ban on Pfizer's cough syrup was part of a wider notice issued by the government over the weekend ordering prohibition of the sale and manufacture of 344 combination drugs that a panel of experts found posed a risk to humans.